Cyclopharm Ltd
ASX:CYC
P/E
Price to Earnings
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
Market Cap | P/E | ||||
---|---|---|---|---|---|
AU |
C
|
Cyclopharm Ltd
ASX:CYC
|
157.1m AUD | -33.4 | |
US |
Abbott Laboratories
NYSE:ABT
|
179.9B USD | 32 | ||
US |
Intuitive Surgical Inc
NASDAQ:ISRG
|
135.5B USD | 68.3 | ||
US |
Stryker Corp
NYSE:SYK
|
123.1B USD | 36.6 | ||
IE |
Medtronic PLC
NYSE:MDT
|
111.3B USD | 26.5 | ||
US |
Boston Scientific Corp
NYSE:BSX
|
107.2B USD | 60.7 | ||
US |
Becton Dickinson and Co
NYSE:BDX
|
67.8B USD | 55.7 | ||
DE |
Siemens Healthineers AG
XETRA:SHL
|
59.2B EUR | 39 | ||
CN |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
375.2B CNY | 30.8 | ||
US |
Edwards Lifesciences Corp
NYSE:EW
|
51.5B USD | 36.6 | ||
US |
Dexcom Inc
NASDAQ:DXCM
|
49.5B USD | 77.4 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.